CancerDrs

Cervical Cancer clinical trials in Florida

66 actively recruiting cervical cancer trials at 38 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • AdventHealth Orlando — Orlando, Florida
  • Orlando Health Cancer Institute — Orlando, Florida
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Florida:
  • Mount Sinai Medical Center — Miami Beach, Florida
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Florida:
  • Research Site — Fort Myers, Florida
  • Research Site — Jacksonville, Florida
  • Research Site — Orlando, Florida
  • Research Site — St. Petersburg, Florida
  • Research Site — West Palm Beach, Florida
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Florida:
  • Site 12 — Fort Myers, Florida
  • Site 123 — Jacksonville, Florida
  • Site 9 — Orlando, Florida
  • Site 138 — Tampa, Florida
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Florida:
  • Florida Cancer Specialists South — Fort Myers, Florida
  • University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
  • AdventHealth Medical Group Oncology and Hematology at Orlando — Orlando, Florida
  • Florida Cancer Specialists North Region — St. Petersburg, Florida
  • Florida Cancer Specialists East — West Palm Beach, Florida
Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Florida:
  • GSK Investigational Site — St. Petersburg, Florida
  • GSK Investigational Site — Tamarac, Florida
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Florida:
  • Mount Sinai Comprehensive Cancer Center ( Site 6000) — Miami Beach, Florida
  • Florida Cancer Specialists - East ( Site 7000) — West Palm Beach, Florida
Phase 2, Phase 3 Recruiting Industry

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…

Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in Florida:
  • Miami Cancer Institute — Miami, Florida
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Florida:
  • Mayo Clinic in Florida — Jacksonville, Florida
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Florida:
  • Sarasota Memorial Hospital-Venice — North Venice, Florida
  • Moffitt Cancer Center at SouthShore — Ruskin, Florida
  • Florida Cancer Specialists - Sarasota — Sarasota, Florida
  • Florida Cancer Specialists - Sarasota Downtown — Sarasota, Florida
  • Sarasota Memorial Hospital — Sarasota, Florida
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Florida:
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
  • Nicklaus Children's Hospital — Miami, Florida
  • Arnold Palmer Hospital for Children — Orlando, Florida
  • Nemours Children's Hospital — Orlando, Florida
Phase 2 Recruiting Industry

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…

Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Florida:
  • Mayo Clinical — Jacksonville, Florida
  • University of Miami — Miami, Florida
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Florida:
  • Florida Cancer Specialists — Sarasota, Florida
  • Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Florida:
  • Florida Cancer Specialists - South — Fort Myers, Florida
  • Florida Cancer Specialists - Lake Nona — Orlando, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Florida Cancer Specialists - East — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in Florida:
  • Research Site 117 — Coral Gables, Florida
  • D&H Cancer Research Center LLC — Margate, Florida
  • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
  • BRCR global — Plantation, Florida
  • Florida Cancer Specialists — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Florida:
  • Florida Cancer Specialists - Lake Nona — Orlando, Florida
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Florida:
  • Holy Cross Hospital (site 213) — Fort Lauderdale, Florida
  • Memorial Cancer Institute at Memorial Healthcare Systems (site 132) — Pembroke Pines, Florida
Phase 1, Phase 2 Recruiting Industry

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered eithe…

Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Florida:
  • Sylvester Comprehensive Cancer Center - Miami — Miami, Florida
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Florida:
  • University of Miami — Miami, Florida
  • Biogenix — Miami, Florida
Phase 2 Recruiting Academic/Other

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05307939
Sites in Florida:
  • Baptist Alliance MCI (Data Collection Only) — Miami, Florida
Phase 2 Recruiting Academic/Other

Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04870762
Sites in Florida:
  • Baptist MD Anderson Cancer Center — Jacksonville, Florida
Phase 2 Recruiting Academic/Other

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…

Sponsor: Massachusetts General Hospital
NCT ID: NCT05668962
Sites in Florida:
  • Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …

Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Florida:
  • Moffitt Cancer Center — Tampa, Florida

Showing 25 of 66 trials with sites in Florida. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15